Rewriting the Kidney University of Bristol’s Gene Therapy for Rare Childhood Nephrotic Syndrome

Researchers at the University of Bristol have patented a gene therapy approach for treating a severe inherited form of kidney disease in children – using an adeno-associated virus (AAV) vector to deliver a corrective gene directly to the kidney’s specialised filtering cells. The invention targets the root genetic cause of certain monogenic nephrotic syndromes, potentially offering a transformative treatment for children with a condition that often progresses to kidney failure.

The Problem

Nephrotic syndrome is the most common primary kidney disease in children, affecting approximately 2 in every 100,000 children under 16. It is characterised by the kidneys leaking large amounts of protein into the urine (proteinuria), leading to low blood protein levels, fluid retention (oedema) and elevated blood lipids. While most childhood cases respond to steroid treatment, a significant minority – roughly 20 per cent – are steroid-resistant and have a far worse prognosis.

Among these steroid-resistant cases, a subset are caused by mutations in single genes – monogenic nephrotic syndrome. Key genes involved include NPHS1 (encoding nephrin) and NPHS2 (encoding podocin), proteins that are critical to the structure and function of the glomerular filtration barrier in the kidney. When these proteins are absent or defective, the barrier breaks down and protein leaks through.

For children with these genetic forms of nephrotic syndrome, there is currently no specific treatment. Many progress to end-stage kidney disease requiring dialysis or transplantation – a devastating outcome for a child that imposes enormous burdens on the patient, family and health system. A therapy that could correct the underlying genetic defect and restore the function of the filtration barrier would be genuinely transformative.

What This Invention Does

The University of Bristol’s gene therapy uses an AAV vector – a small, naturally occurring virus engineered to be safe and to carry therapeutic genetic material – to deliver a corrective transgene to the kidney’s podocytes, the specialised cells that form the critical filtration barrier.

The key innovation is the use of a minimal nephrin promoter (NPHS1) or podocin promoter (NPHS2) to drive expression of the therapeutic transgene specifically in podocytes. Promoters control which cells a gene is active in; by using a promoter that is naturally only active in podocytes, the therapy ensures the corrective gene is expressed exactly where it is needed – in the kidney’s filtration cells – without off-target expression in other tissues.

This targeted, cell-specific delivery approach minimises the risk of unintended effects while maximising therapeutic efficacy in the affected tissue. The AAV vector itself has a well-established safety profile from use in other gene therapy applications.

Key Features

Podocyte-targeted gene delivery. The use of minimal nephrin (NPHS1) or podocin (NPHS2) promoters restricts transgene expression to podocytes – the specific kidney cells where the therapeutic protein is needed – avoiding off-target expression.

AAV vector platform. The therapy uses adeno-associated virus vectors, which have an established safety record in gene therapy and can deliver genetic material to non-dividing cells such as kidney podocytes without integrating into the host genome.

Root cause treatment. By delivering a functional copy of the mutated gene, the therapy addresses the genetic cause of the filtration barrier defect rather than managing the downstream symptoms of protein leakage.

Monogenic nephrotic syndrome focus. The invention specifically targets heritable forms caused by single gene mutations – the group of patients most likely to benefit from a gene correction approach and for whom no existing specific treatment exists.

Paediatric application. Nephrotic syndrome is predominantly a childhood disease, and a gene therapy that could be administered early and potentially provide lasting benefit addresses one of the most serious unmet needs in paediatric nephrology.

Who Is Behind It?

The University of Bristol is a leading UK research university with internationally recognised programmes in kidney disease research. The inventors are Moin Ahson Saleem-Uddin and Gavin Iain Welsh. This application is a divisional of AU 2020208997. The application is managed by Davies Collison Cave Pty Ltd in Milton, Queensland.

Why It Matters

Paediatric kidney failure is one of the most difficult and costly outcomes in medicine. A child who progresses to end-stage renal disease faces decades of dialysis or repeated transplantation, with profound effects on quality of life, educational attainment, family functioning and healthcare resource utilisation. The gene therapy approaches developed by University of Bristol researchers, targeting the specific genetic defects that cause steroid-resistant nephrotic syndrome, represent a potential path to a durable, specific treatment for a group of patients who currently have very limited options.

Gene therapy for kidney disease has historically been technically challenging, but advances in AAV vector design and cell-specific promoter engineering are making previously impractical therapeutic concepts feasible. With IPC classifications covering gene therapy (A61K 48/00) and viral vectors (C12N 15/861), the patent sits at the frontier of genetic medicine applied to one of childhood’s most serious kidney conditions.

---

AU 2026201536 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Nephrotic syndrome in children can result from mutations in genes encoding proteins essential to the glomerular filtration barrier, particularly nephrin and podocin. These steroid-resistant forms carry a high risk of progression to kidney failure, and no specific treatment currently exists.

Adeno-associated virus vectors have an established safety record in gene therapy and are capable of delivering corrective genes to non-dividing cells such as podocytes, making them an attractive platform for cell-specific kidney therapies.